Synthesis and anti-HIV-1 activities of new pyrimido[5,4-b]indoles

Farmaco

Volumn 54, Issue 4, 1999, Pages 255-264

  Merino, Isidro ^a   Monge, Antonio ^a   Font, María ^a   Martínez De Irujo, Juan José ^b   Alberdi, Elena ^b   Santiago, Esteban ^b   Prieto, Isidro ^b   Lasarte, Juan José ^b   Sarobe, Pablo ^b   Borrás, Francisco ^b  

^a Ctro Invest Farmacobiologia A   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

HIV 1 RT inhibitors; HLT4lacZ 1(IIIB) cells; Pyrimido 5,4 b indoles

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIMIDO[5,4 B]INDOLE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANTI-HIV AGENTS; CELL LINE; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; HIV-1; HUMANS; INDOLES; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033617554     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(99)00035-X     Document Type: Article

References (26)

1. Miyasaka T., Tanaka H., Baba M., Hayakawa H., Walker R.T., Balzarini J., De Clercq E. A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 32:1989;2507-2509.
2. Debyser Z., Pauwels R., Andries K., Desmyter J., Kukla M., Janssen P.A.J., De Clercq E. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione derivatives. Proc. Natl. Acad. Sci. USA. 88:1991;1451-1455.
3. Romero D.L., Morge R.A., Biles C., Berrios-Pena N., May P.D., Palmer J.R., Johnson P.D., Smith H.W., Busso M., Tan C.-K., Voorman R.L., Reusser F., Althaus I.W., Downey K.M., So A.G., Resnick L., Tarpley W.G., Aristoff P.A. Discovery, synthesis, and bioactivity of bis(heteroaryl)piperazines. 1. A novel class of non-nucleoside HIV-1 reverse transcriptase inhibitors. J. Med. Chem. 37:1994;999-1014.
4. Balzarini J., Pérez-Pérez M.J., San Félix A., Camarasa M.J., Bathurst I.C., Barr P.J., De Clercq E. Kinetics of inhibition of human immunodeficiency virus type I (HIV-1) reverse transcriptase by the novel HIV-1 specific nucleoside analogue [2′,5′-bis-O-(t-butyldimethylsilyl)-β-D-ribofuranosyl]- 3′-spiro-5′′-(4′′-amino-1′′, 2′′-oxathiole-2′′,2′′-dioxide)thymine (TSAO-T). J. Biol. Med. 267:1992;11831-11838.
5. Cushman M., Casimiro-García A., Hejchman E., Ruell J.A., Huang M., Schaeffer C.A., Williamson K., Rice W.G., Buckheit R.W. Jr. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors. J. Med. Chem. 41:1998;2076-2089.
6. De Clercq E. HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Med. Res. Rev. 13:1993;229-258.
7. De Vreese K., Debyser Z., Vandamme A.M., Pauwels R., Desmyter J., De Clercq E., Anne J. Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis. Virology. 188:1992;900-904.
8. Sardana V.V., Emini E.A., Gotlib L., Graham D.J., Lineberger D.W., Long W.J., Schlabach A.J., Wolfgang J.A., Condra J.H. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple non-nucleoside inhibitors. J. Biol. Chem. 267:1992;17526-17530.
9. Kleim J.-P., Winkler I., Rösner M., Kisch R., Rübsamen-Waigmann H., Paerssens A., Riess G. In vitro selection for different mutational patterns in de HIV-1 reverse transcriptase using high and low selective pressure of the non-nucleoside reverse transcriptase inhibitor HBY 097. Virology. 231:1997;112-118.
10. Balzarini J., Karlsson A., De Clercq E. Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives. Mol. Pharmacol. 44:1993;694-701.
11. Balzarini J., Karlsson A., Pérez-Pérez M.J., Camarasa M.J., Tarpley W.G., De Clercq E. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern that does treatment with single-drug therapy. J. Virol. 67:1993;5353-5359.
12. De Clercq E. HIV resistance to reverse transcriptase inhibitors. Biochem. Pharmacol. 47:1994;155-169.
13. Font M., Monge A., Cuartero A., Elorriaga A., Martínez de Irujo J.J., Alberdi E., Santiago E., Prieto I., Lasarte J.J., Sarobe P., Borrás F. Indoles and pyridazino[4,5-b]indoles as non-nucleoside analog inhibitors of HIV-1 reverse transcriptase. Eur. J. Med. Chem. 30:1995;963-971.
14. A. Monge, M.J. Losa, M.J. Fidalgo, E. Nadal, A. Cuartero, C. Sanmartín, E. Alvarez, I. Merino, M. Font, J.J. Martínez de Irujo, E. Alberdi, E. Santiago, I. Prieto, J.J. Lasarte, P. Sarobe, F. Borrás, New HIV-1 inhibitors, derived from 1,2-dihydroquinoline, Poster No. 213, 13th Int. Symp. Med. Chem., Paris, France, 1994.
15. A. Monge, I. Merino, M. Font, J.J. Martínez de Irujo, E. Alberdi, E. Santiago, I. Prieto, J.J. Lasarte, P. Sarobe, F. Borrás, Synthesis and anti-HIV-1 activities of new pyrimido[5,4-b]indoles, Poster No. 8.06, 14th Int. Symp. Med. Chem., Maastricht, The Netherlands, 1996.
16. Romero D.L., Morge R.A., Genin M.J., Biles C., Busso M., Resnick L., Althaus I.W., Reusser F., Thomas R.C., Tarpley W.G. Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3-[(1-methylethyl)amino] pyridinyl]piperazine mono-methanesulfonate U-90152s), a second-generation clinical candidate. J. Med. Chem. 36:1993;1505-1508.
17. Strekowski L., Mokrosz J.L., Honkan V.A., Czarny A., Cegla M.T., Wydra R.L., Patterson S.E., Schinazi R.F. Synthesis and quantitative structure-activity relationship analysis of 2-(aryl or heteroaryl)quinolin-4-amines, a new class of anti-HIV-1 agents. J. Med. Chem. 34:1991;1739-1746.
18. Unangts P.C. Pyrido[1′,2′:1,2]pyrimido[5,4-d]indoles: a new heterocyclic ring system. J. Heterocycl. Chem. 20:1983;495-499.
19. Monge A., Martínez-Crespo F.J., Villanueva M.A., Font M., Santiago E., Martínez-Irujo J.J., Alberdi E., López-Unzu M.J., Cenarruzabeitia E., Castiella E., Frechilla D. New 4-amino-7,8-dimethoxy-5H-pyrimido[5,4-b]indole derivatives: synthesis and studies as inhibitors of phosphodiesterases. Arch. Pharm. 326:1993;879-885.
20. Shishoo C.J., Devani M.B., Pathak U.S., Ananthan S., Bhadti V.S., Ullas G.V., Jain K.S., Rathod I.S., Talati D.S., Doshi N.H. Reaction of nitriles under acidic conditions. Part III. A facile synthesis of thienopyrimidin-4(3H)-ones. J. Heterocycl. Chem. 21:1984;375-380.
21. Deibel M.R. Jr., McQuade T.J., Brunner D.P., Tarpley W.G. Denaturation/refolding of purified recombinant HIV reverse transcriptase yields monomeric enzyme with high enzymatic activity. AIDS Res. Hum. Retrovir. 6:1990;329-340.
22. Tan C.-K., Zhang J., Li Z.Y., Tarpley W.G., Downey K.M., So A.G. Funcional characterization of RNA-dependent DNA polimerase and RNase H activities of a recombinant HIV reverse transcriptase. Biochemistry. 30:1991;2651-2655.
23. Sharma S.K., Evans D.B., Vosters A.F., McQuade T.J., Tarpley W.G. Metal-affinity chromatography of recombinant HIV-1 reverse transcriptase containing a human renin cleavable metal binding domain. Biotechnol. Appl. Biochem. 14:1991;69-81.
24. Rocancourt D., Bonnerot C., Jouin H., Emerman M., Nicolas J.F. Activation of a β-galactosidase recombinant provirus: application of titration of human immunodeficiency virus (HIV) and HIV-infected cells. J. Virol. 64:1990;2660-2668.
25. Aggarwal B.B., Kohr W.J., Hass P.E., Moffat B., Spencer S.A., Henzel W.J., Bringman T.S., Nedwin G.E., Goeddel D.V., Harkins R.N. Human tumor necrosis factor. Production, purification, and characterization. J. Biol. Chem. 260:1985;2345-2354.
26. Nanni R.G., Ding J., Jacobo-Molina A., Hughes S.H.:, Arnold E. Review of HIV-1 reverse transcriptase three-dimensional structure: implications for drug design. Perspect. Drug Discov. Des. 1:1993;129-150.